<DOC>
	<DOCNO>NCT00694525</DOCNO>
	<brief_summary>21-hydroxylase deficiency ( 21-OHD ) inherit disorder result mutation CYP21A2 gene . It affect adrenal gland common cause congenital adrenal hyperplasia ( CAH ) . 21-OHD CAH cause body produce insufficient amount cortisol excess androgen , type hormone produce male characteristic . The primary treatment 21-OHD CAH , glucocorticoid replacement therapy , show cause bone loss . However , elevate hormone level cause 21-OHD CAH may increase production protein osteoprotegerin ( OPG ) , turn may protect bone loss . This study compare bone density OPG level woman 21-OHD CAH undergone lifetime glucocorticoid replacement therapy woman neither criterion . In , study aim determine relationship OPG bone loss .</brief_summary>
	<brief_title>Role Protein Osteoprotegerin Bone Health Women With Congenital Adrenal Hyperplasia</brief_title>
	<detailed_description>Because excess androgen cause 21-OHD CAH , woman CAH may exhibit male-like characteristic . Glucocorticoids member class drug call corticosteroid , use hormone replacement therapy . In order counteract effect 21-OHD CAH , woman disease give hormone replacement therapy glucocorticoid begin infancy . Glucocorticoids know cause bone loss . Despite many year treatment glucocorticoid , however , young woman 21-OHD CAH seem protect bone loss . Researchers believe increase androgen level woman lead increase estrogen level , turn increase OPG production . The increase OPG level may protect woman bone loss . This study evaluate bone density OPG level woman without 21-OHD CAH determine relationship OPG bone loss . Participants observational study attend one study visit . At visit , undergo blood draw ; scan low spine , hip , forearm ; height weight measurement ; body fat analysis test . This last test entail weak painless electrical signal send foot foot . Participants attend follow-up visit study .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Adrenocortical Hyperfunction</mesh_term>
	<criteria>For People 21OHD CAH : 21OHD CAH document molecular genetic analysis ( mutation CYP21A2 gene parental allele ) Treatment glucocorticoid replacement since infancy ( begin within first year ) Available hormonal data treatment detail 5 year prior study entry Premenopausal For Healthy Controls : No diagnosis 21OHD CAH , confirm molecular genetic analysis No first degree relative enrol 21OHD CAHparticipant Premenopausal Medical disorder treatment medication know affect bone density ( glucocorticoid 21OHD CAH patient ) , include , limited growth hormone , IGFI , depomedroxyprogesterone acetate , biphosphonates , oral contraceptive , androgen , thyroxine , aromatase inhibitor Pregnant Any smoking within 6 month prior study entry Cardiac pacemaker implant electronic medical device</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>21OHD</keyword>
	<keyword>21-hydroxylase deficiency</keyword>
	<keyword>CAH</keyword>
</DOC>